KaiDi Co. announced that its robot-related products are still in the development phase and will not generate revenue in the short term. The company's stock experienced significant price fluctuations, prompting this clarification. Separately, Hanyu Pharmaceutical signed a framework agreement for peptide raw material sales amounting to at least 327 million yuan, and the news also mentioned global free access to ChatGPT Plus and other unrelated financial news. AI
RANK_REASON The cluster contains multiple unrelated news items, including a clarification from KaiDi Co. about its product development status and a separate financial agreement by Hanyu Pharmaceutical, making it a digest rather than a single coherent story.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →